<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883022</url>
  </required_header>
  <id_info>
    <org_study_id>2017-10-008A</org_study_id>
    <nct_id>NCT03883022</nct_id>
  </id_info>
  <brief_title>Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery</brief_title>
  <official_title>Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Deep surgical site infection (DSSI) is one of the most challenging complications for spinal
      surgeons and can lead to a poor clinical outcome. This ambispective study was designed to
      examine the effect of vancomycin powder mixed with autogenous bone graft and bone substitute
      on preventing deep surgical site infection (DSSI) in degenerative lumbar fusion surgeries as
      well as any interference with bony fusion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 12, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bony fusion status</measure>
    <time_frame>Post-operative 1 month</time_frame>
    <description>The bony fusion status (Lenke criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bony fusion status</measure>
    <time_frame>Post-operative 3 months</time_frame>
    <description>The bony fusion status (Lenke criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bony fusion status</measure>
    <time_frame>Post-operative 6 months</time_frame>
    <description>The bony fusion status (Lenke criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bony fusion status</measure>
    <time_frame>Post-operative 1 year</time_frame>
    <description>The bony fusion status (Lenke criteria)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 1 month</time_frame>
    <description>Functional outcomes, visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 3 months</time_frame>
    <description>Functional outcomes, visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 6 months</time_frame>
    <description>Functional outcomes, visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 1 year</time_frame>
    <description>Functional outcomes,visual analogue scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 1 months</time_frame>
    <description>Functional outcomes,oswestry disability index (ODI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 3 months</time_frame>
    <description>Functional outcomes, oswestry disability index (ODI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 6 months</time_frame>
    <description>Functional outcomes, oswestry disability index (ODI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>Post-operative 1 year</time_frame>
    <description>Functional outcomes, oswestry disability index (ODI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vancomycin concentration</measure>
    <time_frame>Post-operative days 1</time_frame>
    <description>Vancomycin concentration was checked for both the serum and drainage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancomycin concentration</measure>
    <time_frame>Post-operative days 3</time_frame>
    <description>Vancomycin concentration was checked for both the serum and drainage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Spinal Fusion</condition>
  <condition>Spinal Stenosis</condition>
  <condition>Spondylolisthesis</condition>
  <arm_group>
    <arm_group_label>Vancomycin (V Group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Vancomycin (NV Group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>with U-VANCO (vancomycin hydrochloride)</intervention_name>
    <description>1 gm or 2 gm mixed with autogenous cancellous bone graft</description>
    <arm_group_label>Vancomycin (V Group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>without U-VANCO (vancomycin hydrochloride)</intervention_name>
    <description>no vancomycin added</description>
    <arm_group_label>Without Vancomycin (NV Group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have instrumented spine fusion surgery due to failed conservative
             treatment (bed rest, medication, rehabilitation programs) for 3 to 6 months

          -  Patients who are willing to sign the surgical permit after the surgeon explains all
             surgical procedures along with the surgical risks

          -  Patients who fully understand the surgical procedures as well as the surgical risks
             and are willing to sign the surgical permit and the inform consent

          -  Patients who agree one more blood withdrawal after operation

        Exclusion Criteria:

          -  Patients who agree to accept the spine surgery but do not agree to sign the inform
             consent

          -  Patients who have allergic reaction to vancomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Tien Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shih-Tien Wang, MD</last_name>
    <phone>886-2-28757557</phone>
    <phone_ext>9</phone_ext>
    <email>stwang@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih-Tien Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 10, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep surgical site infection</keyword>
  <keyword>Vancomycin-impregnated bone graft</keyword>
  <keyword>Spine surgery</keyword>
  <keyword>Degenerative lumbar disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

